Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Interventional, Adaptive, Clinical Trial to Evaluate the Efficacy and Safety of Tralokinumab 300 mg Every Second Week Monotherapy Compared With Placebo in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

NCT05958407 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT05958407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05958407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Interventional, Adaptive, Clinical Trial to Evaluate the Efficacy and Safety of Tralokinumab 300 mg Every Second Week Monotherapy Compared With Placebo in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
Lead sponsor
LEO Pharma
Phase
Phase 3
Overall status
Completed
Start date
August 28, 2023
Completion date
September 22, 2025
Enrollment
235 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, atopic hand eczema